ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2668

CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit

Nazgol Haddadi1, Khashayar Afshari1, Yuqing Wang1, Carolina S. Lopes1, Chee-Huat L. Eng2, Nuria Martinez-Gutierrez1, Leah Whiteman1, Kevin Wei3, Kirsten Frieda2, Stefania Gallucci1, Misha Rosenbach4, Ruth Ann Vleugels5, John E. Harris1, Manuel Garber1 and Mehdi Rashighi1, 1UMass Chan Medical School, Worcester, MA, 2Spatial Genomics, Inc., Pasadena, CA, 3Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 4University of Pennsylvania, Philadelphia, PA, 5Brigham and Women's Hospital, Chestnut Hill, MA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, dermatomyositis, Environmental factors, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)

Session Type: Abstract Session

Session Time: 12:45PM-1:00PM

Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous lupus erythematosus (CLE) and dermatomyositis (DM), UV exposure can worsen disease. The biological basis for this photosensitivity remains unclear.

Methods: We used a multi-omics approach—single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and proteomics—to analyze lesional and non-lesional skin from patients with DM, CLE, vitiligo, psoriasis, and healthy controls. In vivo, a photoprovocation test was performed on sun-protected skin of healthy volunteers, DM, and CLE patients; post-irradiation biopsies were analyzed by flow cytometry and spatial transcriptomics. In vitro, keratinocytes were treated with UVB ± IFN-β. Supernatants were applied to monocyte-derived dendritic cells (moDCs) generated from PBMCs, and their activation was assessed.

Results: CD14⁺ myeloid cells, which resembled monocyte-derived dendritic cells (moDCs) in culture, were the only immune population distinguishing photosensitive (CLE, DM) from photoresponsive (psoriasis, vitiligo) diseases. These cells were enriched in lesional DM (43%) and CLE (12%) compared to controls ( < 0.3%) and localized near the dermo-epidermal junction, adjacent to cytotoxic CD4⁺ T cells. CD14⁺ myeloid cells expressed IFNB1 and MMP9, suggesting involvement in IFN-I signaling and tissue remodeling. UVB photoprovocation confirmed increased recruitment of CD14⁺ myeloid cells to the skin, more so in DM and CLE patients. IFN-β priming sensitized keratinocytes to UVB-induced death and enhanced secretion of TNF-α and IL-6, which activated moDCs. Upon activation, moDCs release chemokines promoting immune cell recruitment, amplified in the presence of IFN-β.

Conclusion: Our findings reveal a UVB-induced inflammatory circuit driven by IFN-β–primed keratinocytes and CD14⁺ myeloid cells in CLE and DM. By defining this keratinocyte–myeloid interaction, we highlight new opportunities for targeted therapies that may prevent lesion flares in photosensitive patients.

Supporting image 1CD14⁺ myeloid cells (MC_CD14) are expanded in dermatomyositis and lupus skin in our single-cell RNA sequencing dataset (heatmap, left) and show the highest IFNB1 expression among dendritic cell subsets (violin plot, right).

Supporting image 2The dot plot (top) shows shared marker expression between CD14⁺ myeloid subsets identified by scRNA-seq and spatial single-cell transcriptomics (SeqFISH+). The MC_Inf transcriptional signature aligns with the scRNA-seq-defined CD14⁺ myeloid profile and maps to cells spatially enriched near the dermo-epidermal junction, as illustrated in the bottom panels.

Supporting image 3Schematic and heatmaps showing moDCs stimulated with supernatants from UV-treated keratinocytes. Exposure to supernatants from UVB-damaged keratinocytes, particularly in the presence of IFN-β, induced a transcriptional program enriched for MC_Inf markers (e.g., CD80, CD86, CCL4, MMP9), consistent with acquisition of a pro-inflammatory phenotype.


Disclosures: N. Haddadi: None; K. Afshari: None; Y. Wang: None; C. Lopes: None; C. Eng: None; N. Martinez-Gutierrez: None; L. Whiteman: None; K. Wei: 10X Genomics, 5, anaptysbio, 2, Gilead, 5, Merck/MSD, 5, Mestag, 2, Pfizer, 2; K. Frieda: None; S. Gallucci: None; M. Rosenbach: None; R. Vleugels: None; J. Harris: None; M. Garber: None; M. Rashighi: None.

To cite this abstract in AMA style:

Haddadi N, Afshari K, Wang Y, Lopes C, Eng C, Martinez-Gutierrez N, Whiteman L, Wei K, Frieda K, Gallucci S, Rosenbach M, Vleugels R, Harris J, Garber M, Rashighi M. CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cd14%e2%81%ba-myeloid-cells-mediate-uvb-photosensitivity-in-autoimmune-skin-disease-via-a-spatially-resolved-inflammatory-circuit/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd14%e2%81%ba-myeloid-cells-mediate-uvb-photosensitivity-in-autoimmune-skin-disease-via-a-spatially-resolved-inflammatory-circuit/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology